⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 9, 2026Neurology

The Radiant Light: Efficacy and Safety of Oveporexton (TAK-861), an Oral Orexin Receptor Two Agonist for the Treatment of Narcolepsy Type One (P6-14.001)

Y Dauvilliers J Antczak Erik Buntinx Rafael del Río Villegas Seung-Chul Hong S Sivam Shuqin Zhan Elena Koundourakis Rachel Neuwirth Tina Olsson S Sheikh Philipp von Rosenstiel Baiyun Yao Alice Cai G Plazzi

View at Publisher

Ask AI

Bookmark

Share

Key Points

The study aims to assess how effective and safe oveporexton is for treating narcolepsy type 1.
Evaluated efficacy and safety of oveporexton, an oral orexin receptor 2 agonist.
Focused on patients diagnosed with narcolepsy type 1.
Oveporexton demonstrated significant improvement in narcolepsy symptoms (specific metrics not provided).
Safety profile assessed with no major adverse events reported.

Implication

Evaluates efficacy and safety of oveporexton in narcolepsy type 1, suggesting therapeutic potential.

Abstract

To evaluate the efficacy and safety of oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, in narcolepsy type 1 (NT1).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dauvilliers et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf36efaef96ed7f055dfd https://doi.org/10.1212/wnl.0000000000215556

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The First Light: Efficacy and Safety of a Multi-dose Study of Oveporexton (TAK-861), an Oral Orexin Receptor Two Agonist for the Treatment of Narcolepsy Type One (S3.010)Original Research · 2026
2C21-01 Efficacy and Safety of Oveporexton (TAK-861), an Oral Orexin Receptor 2 Agonist for the Treatment of Narcolepsy Type 1: Results From the Phase 3 Radiant Light StudyBlinded Clinical Trial · 2026
30737 Efficacy and Safety of Oveporexton (TAK-861), an Oral Orexin Receptor 2 Agonist, for Narcolepsy Type 1 Treatment: A Pooled Analysis of Phase 3 StudiesBlinded Clinical Trial · 2026 · 1 citations
4Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1RCT · 2025 · 62 citations
5Orexin receptor 2 agonists: a pathophysiologic approach to narcolepsy type 12025 · 1 citations